Abstract
Severe COVID-19 is reflected by significant changes in urine peptides. Based on this observation, a clinical test predicting COVID-19 severity, CoV50, was developed and registered as in vitro diagnostic in Germany. We have hypothesized that molecular changes displayed by CoV50, likely reflective of endothelial damage, may be reversed by specific drugs. Such an impact by a drug could indicate potential benefits in the context of COVID-19. To test this hypothesis, urinary peptide data from patients without COVID-19 prior to and after drug treatment were collected from the human urinary proteome database. The drugs chosen were selected based on availability of sufficient number of participants in the dataset (n > 20) and potential value of drug therapies in the treatment of COVID-19 based on reports in the literature. In these participants without COVID-19, spironolactone did not demonstrate a significant impact on CoV50 scoring. Empagliflozin treatment resulted in a significant change in CoV50 scoring, indicative of a potential therapeutic benefit. The study serves as a proof-of-principle for a drug repurposing approach based on human urinary peptide signatures. The results support the initiation of a randomized control trial testing a potential positive effect of empagliflozin for severe COVID-19, possibly via endothelial protective mechanisms.
Keywords: COVID-19; SGLT2 inhibition; drug repurposing; peptides; proteomics; urine.
【저자키워드】 COVID-19, Drug repurposing, proteomics, peptides, Urine, SGLT2 inhibition, 【초록키워드】 Treatment, Drug repurposing, proteomics, therapy, severe COVID-19, diagnostic, COVID-19 severity, peptide, drugs, endothelial damage, drug, in vitro, database, Randomized, Germany, peptides, Urine, dataset, proteome, drug treatment, molecular, change, Hypothesis, in urine, drug therapies, protective mechanisms, Support, observation, Therapeutic benefit, endothelial, spironolactone, Empagliflozin, principle, Registered, participant, proof, potential benefits, positive, approach, selected, significant changes in, collected, reflected, potential benefit, reversed, patients without COVID-19, trial testing, 【제목키워드】 in-silico, change,